Global Fractional Flow Reserve Market is segmented By Device Type (Pressure Guidewire, Monitoring Systems, Non-Invasive Scanning Systems) By Measurement Method (Invasive FFR, Non-Invasive FFR) By Application (Single-Vessel CAD Evaluation, Multi-Vessel CAD Evaluation, CABG Assessment, Others) By End User (Hospitals, Ambulatory Surgical Centers, Cardiac Catheterization Labs, Others) and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Report Overview
The Global Fractional Flow Reserve Market reached US$ 881.35 million in 2023 and is expected to reach US$ 2,047.68 million by 2031, growing at a CAGR of 11.27% during the forecast period 2024-2031.
A fractional flow reserve assessment measures the severity of coronary artery stenosis by comparing blood flow on either side of the blockage. A result below 1 may indicate medical treatment or angioplasty, aiding the provider in treatment selection.
Market Scope
| Metrics | Details |
| CAGR | 11.27% |
| Market Size Available for Years | 2022-2031 |
| Estimation Forecast Period | 2024-2031 |
| Revenue Units | Value (US$ Mn) |
| Segments Covered | Device Type, Measurement Method, Application, End User |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Largest Region | North America |
| Fastest Growing Region | Asia-Pacific |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For more details on this report – Request for Sample
Market Dynamics: Drivers & Restraints
Rise in the prevalence of coronary artery diseases
With the rising incidence of coronary artery diseases worldwide, there's a growing demand for effective diagnostic tools like FFR to assess coronary artery disease severity and guide treatment decisions.
For instance, according to an article published in NCBI 2023, Coronary artery disease (CAD) accounts for approximately 610,000 deaths annually (estimated 1 in 4 deaths) and is the leading cause of mortality in the United States. It is the third leading cause of mortality worldwide and is associated with 17.8 million deaths annually. Healthcare services for CAD are estimated to cost greater than 200 billion dollars annually in the United States. While CAD is a significant cause of death and disability, it is preventable.
Interventional cardiologists are hesitant to adopt the FFR
Despite the benefits of Functional Fractional Echocardiography (FFR) over angiography, many interventional cardiologists still rely on visual assessment of stenosis severity. This is due to logistical challenges, potential complications, and uncertainty about optimal performance and interpretation. FFR is not technically challenging, but several procedural aspects must be considered to avoid incorrect measurements or misinterpretation of results. As a result, interventional cardiologists are reluctant to adopt FFR, which is expected to hinder market growth in the coming years.
Market Segment Analysis
The global fractional flow reserve market is segmented based on device type, measurement method, application end-user and region.
The pressure guidewires from the device type segment accounted for approximately 52.3% of the fractional flow reserve market share
The pressure guidewires from the device type segment accounted for approximately 42.3%. The pressure guidewires segment is predicted to experience significant growth in the forecast period, as pressure guidewires are crucial in heart surgery procedures and serve as a navigator's tool.
For instance, as per the OECD statistics published in November 2022, around 11,029 transluminal coronary angioplasty surgeries were performed in Norway in the year 2021, and nearly 10,330 procedures were performed in Portugal. Thus, the large number of angioplasty procedures is expected to increase the demand for guidewires, which in turn is expected to propel the growth of the market segment over the forecast period.
Moreover, in October 2020, Royal Philips, a global leader in health technology, has introduced OmniWire, the world's first solid core pressure wire for coronary artery interventional procedures. With its breakthrough solid core construction, physicians can more easily move the wire in the patient's circulatory system to measure blood pressure along the vessel and guide the delivery of catheters and stents.
Market Geographical Share
North America is estimated to hold about 38.4% of the total market share throughout the forecast period
North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to factors like favorable government policies aimed at promoting the adoption of medical devices and the presence of a well-established healthcare infrastructure. Moreover, the market in North America is expected to remain highly competitive in the coming years due to novel product launches, FDA clearance and an increasing number of mergers and acquisitions by key industry players.
For instance, in September 2023, Boston Scientific announced the FDA clearance of its next-generation IVUS and fractional flow reserve system designed to improve guidance during PCI.
Furthermore, in July 2021, HeartFlow announced its merger with Longview Acquisition Corp. II to transform into a publicly traded company. Once the merger is completed, the entity will operate under HeartFlow Group Inc. and is expected to be listed on the New York Stock Exchange using the symbol HFLO.
Covid 19 Impact Analysis
The COVID-19 pandemic significantly impacted the fractional flow reserve (FFR) market, affecting market dynamics, growth rates, and performance. Changes in clinical practice, such as reduced unplanned revascularization and myocardial infarction, were evident at 6-month follow-up. Additionally, significant cost savings were achieved during this time, impacting the market beyond the pandemic period. The pandemic moderately affected manufacturing production and impacted market growth to some extent.
Market Competitive Landscape
The major global players in the market include Boston Scientific Corporation, Abbott Laboratories, Koninklijke Philips N.V., CathWorks Ltd., Opsens Inc (Haemonetics), HeartFlow Inc., Siemens Healthineers AG, Pie Medical Imaging B.V., Acist Medical Systems, Medis Imaging among others.
Key Developments
- In July 2022, Medtronic established a strategic partnership with CathWorks, an Israeli-based company. Under the partnership, Medtronic agreed to invest USD 75 million and initiated joint promotion of CathWorks' FFRangio System in the U.S., Japan, and Europe, where the system is already commercially available. The FFRangio System offers an innovative approach to assess CAD, and this collaboration aims to advance its adoption and utilization in key markets worldwide.
- In February 2022, Siemens Healthineers expanded its cardiology portfolio with the launch of Artis Icono Biplane, an angiography system with detectors optimized in size for integrated use in the cath lab. The device employs an angio-derived fractional flow reserve (vFFR).
Why Purchase the Report?
- To visualize the global fractional flow reserve market segmentation based on device type, measurement method, application, end user and region as well as understand key commercial assets and players.
- identify commercial opportunities by analyzing trends and co-development.
- excel data sheet with numerous data points of the fractional flow reserve market level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global fractional flow reserve market report would provide approximately 64 tables, 61 figures and 186 pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
